Abstract:Abstract Background Binding of PD-1 with ligands (e.g. PD-L1) expressed on tumor cells or native antigen-presenting cells results in down-regulation of effector T cell function and represents a potent mechanism of immune evasion across a number of solid tumors and lymphomas especially classical Hodgkin lymphoma (CHL) and aggressive virus-associated B-cell lymphomas. Several biomarkers (different antibodies, gene amplifications and mutations) are being investigated for identifying patients who may benefit from PD-1 checkpoint blockade therapies. It is well known that tumors which strongly express PD-L1 have a high clinical response rate to PD1 blockade. We aimed at identifying the expression of PD-L1 and PD1 in a diverse group of lymphomas. There are several antibodies used to detect PD-L1 expression, however the concordance between these antibodies is not known. We have previously tested concordance of 2 anti-PD-L1 antibodies in histiocytoses [1], but data in lymphomas are lacking. In the current study, we measured PD-L1 expression in lymphoma biopsy samples using 3 antibodies to identify if there was concordance in expression patterns of PD-L1 in various subtypes of lymphomas. Methods Formalin fixed paraffin embedded tissues from 37 patients with lymphomas of B- and T-cell lineages (both EBV-positive and negative) were investigated for the expression of PD-1 (MRQ-22 antibody) and PD-L1 (MAB1561, SP142 and SP263) using automated immunohistochemical methods. Expression of PD-L1 on 5% or more lymphoma cells was considered positive. Results Neoplastic cells expression of PD-L1 was identified in 13/37 cases (35% of all cases). The strongest (3+/>50% cells) and consistent (4/4 cases) expression was observed in Hodgkin RS cells of CHL (2/2 nodular sclerosis and 2/2 lymphocyte depleted). Other B-cell lineage lymphomas positive for expression of PD-L1 included diffuse large B-cell lymphomas (5/9 DLBCL) and lymphomatoid granulomatosis (1/1 LYG). Small lymphocytic lymphoma (n=3), splenic marginal zone lymphoma (n=2) and follicular lymphomas (n=8) were all negative. One of four mantle cell lymphomas (MCL) was borderline (5% of cells) positive. One NK/T-cell lymphoma was strongly (>50% cells) positive; four peripheral T-cell lymphomas (PTCL) and one T cell lymphoblastic lymphoma were negative. PD-L1 expression was observed in both EBV- positive (2/4) and negative (2/3) malignancies. Concordance between any 2 anti-PD-L1 antibodies varied between 86 and 97% (Table 1) with all 3 Abs agreeing in 82%. PD-1 was expressed on malignant cells in 3 cases (2 PTCL and 1 DLBCL); reactive PD-1+ T-lymphocytes were absent in LD CHL and variably present in all other lymphomas. Conclusions Over-expression of PD-L1was detected in classic HD, diffuse large B cell lymphoma, NK/T cell lymphoma and lymphomatoid granulomatosis. A high concordance in detection of PD-L1 between three antibodies indicates little need for companion diagnostic kits, but correlation between clinical responses and level of PDL1 and PD1 expression in lymphoma should be established in future clinical trials. Table 1. Concordance between the PD-L1 antibodies. Antibodies (n) MAB1561 SP142 SP263 MAB1561 (23) -- 20/23 (86%) SP142 (37) -- -- 34/35 (97%) SP263 (35) 19/22 (86%) -- -- References: 1. Gatalica, Z., et al., Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget, 2015. Disclosures Gatalica: Caris Life Sciences: Employment. Arguello:Caris Life Sciences: Employment, Equity Ownership. Reddy:Caris Life Sciences: Employment. Ghosh:Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

Significance of SHP-1 Expression in Benign Lesions of Lymphoid Tissues and Lymphomas

Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma acuminatum and Cervical Cancer

The Expression and Clinical Significance of COX-2 and P-gp in B Cell Lymphoma

[Expression of Tyrosine Phosphatase Containing C-src Homology SH-2 in Benign Prostate Hyperplasia].

The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer.

Expression Of Shh Signaling Pathway Factors In Gastrointestinal Stromal Tumor Tissues And Their Associations With Clinical Pathological Factors

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

The Clinicopathological and Prognostic Implications of Tyrosine Phosphatase SHP2 and Ankyrin Hook1 Gene Expression in Non- Small Cell Lung Cancer Patients Treated with Gemcitabine Plus Platinum As First-Line Chemotherapy

Expressions of Shh and Stathmin in Prostatic Diseases and Their Clinical Significances

Expression and Clinical Significance of Neuropilin-1 in Epstein-Barr Virus-Associated Lymphomas

FOXP1 Expression and Its Clinicopathologic Significance in Nodal and Extranodal Diffuse Large B-cell Lymphoma

Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers

[Significance of p53 protein expression and p53 gene mutation in so-called pulmonary sclerosing hemangioma]

The Clinical Significance Of Apolipoprotein L1 In Head And Neck Squamous Cell Carcinoma

Pan-cancer analysis of the prognostic and immunological roles of SHP-1/ptpn6

BCL-6,CD10 and BCL-2 Protein Expression in B-cell Non-Hodgkin's Lymphoma and Its Clinicopathologic Significance

Characterization of SHCBP1 to Prognosis and Immunological Landscape in Pan-Cancer: Novel Insights to Biomarker and Therapeutic Targets.

SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer

The Significance of Insulinoma-Associated Protein 1 in the Pathological Diagnosis of Small-Cell Lung Cancer in Biopsy Specimens

The significance of p40 expression in sclerosing hemangioma of lung

PD-L1 and PD1 Expression in Lymphomas